ABOS: Phase II trial of sabirnetug targets toxic oligomers in Alzheimer's, with pivotal data due late 2026
The conference highlighted a rapidly growing Alzheimer's market and detailed the phase II ALTITUDE-AD trial of sabirnetug, targeting toxic A-beta oligomers with data expected in late 2026. Strong KOL support, robust trial design, and an innovative EBD program for enhanced brain delivery position th…